β-adrenergic receptor (AR) subtypes are archetypical members of the G protein-coupled receptor (GPCR) superfamily. Whereas both β 1 AR and β 2 AR stimulate the classic G s -adenylyl cyclase-3′,5′-adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling cascade, β 2 AR couples to both G s and G i proteins, activating bifurcated signaling pathways. In the heart, dual coupling of the β 2 AR to G s and G i results in compartmentalization of the G s -stimulated cAMP signal, thus selectively affecting plasma membrane effectors (such as L-type Ca 2+ channels) and bypassing cytoplasmic target proteins (such as phospholamban and myofilament contractile proteins). More important, the β 2 AR-to-G i branch delivers a powerful cell survival signal that counters apoptosis induced by the concurrent G s -mediated signal or by a wide range of assaulting factors. This survival pathway sequentially involves G i , Gβγ, phosphoinositide 3-kinase, and Akt. Furthermore, cardiacspecific transgenic overexpression of βAR subtypes in mice results in distinctly different phenotypes in terms of the likelihood of cardiac hypertrophy and heart failure. These findings indicate that stimulation of the two βAR subtypes activates overlapping, but different, sets of signal transduction mechanisms, and fulfills distinct or even opposing physiological and pathophysiological roles. Because of these differences, selective activation of cardiac β 2 AR may provide catecholamine-dependent inotropic support without cardiotoxic consequences, which might have beneficial effects in the failing heart. Overview G protein-coupled receptors (GPCRs) constitute the largest class of cell surface signaling molecules in eukaryotes and some prokaryotes. They share a common overall structure feature: seven hydrophobic transmembrane helical domains. In the worm Caenorhabditis elegans, GPCR-encoding genes constitute 5% of the genome with ~1100 members (1), whereas there are more than 700 GPCRs in the human genome (2) . By activating their cognate heterotrimeric guanosine triphosphate (GTP) binding proteins (G proteins), GPCRs transduce stimulatory or inhibitory signals for a wide array of endogenous hormones and neurotransmitters, and ambient physical and chemical stimuli, as well as exogenous therapeutic reagents. Occupation of these receptors with agonists promotes guanosine diphosphateguanosine triphosphate (GDP-GTP) exchange on the Gα subunit and subsequent dissociation of Gα from Gβγ, leading to activation of Gα and release of free Gβγ heterodimers (3-6). Both Gα and Gβγ then serve as signaling mediators to directly interact with a variety of effector proteins, including enzymes and ionic channels (7, 8) .
Intracellular propagation of GPCR signaling is an intricate process orchestrated by a myriad of G proteins. In mammals, there are at least 27 Gα, 5 Gβ, and 13 Gγ subtypes (9) . On the basis of the primary sequences of the Gα subunits, G proteins can be divided into four families: G s , G i , G q , and G 12 (10) . Historically, specificity and selectivity in GPCR signaling was thought to be achieved by coupling of a given GPCR to a single class of G proteins. As the prototypical GPCR, β-adrenergic receptor (AR) was found to interact exclusively with G s , which in turn activated adenylyl cyclase (AC), catalyzing 3′,5′-adenosine monophosphate (cAMP) formation. Subsequently, activation of cAMP-dependent protein kinase (PKA, also known as Akinase) would lead to phosphorylation of target proteins. This paradigm, however, has been shifted with the finding that multiple GPCRs can couple to more than one G protein pathway. Whereas the β 1 AR subtype appears to stimulate solely the G s pathway, compelling evidence indicates that β 2 AR conducts a duet of signaling that includes both G s and G i . The additional G i pathway not only reshapes the spatiotemporal pattern of the G s -AC-cAMP signaling, but also delivers G s -independent signals. These βAR subtypes are currently believed to fulfill distinct, sometimes even opposite, physiological and pathological roles. This review will highlight recent advances in our understanding of signal transduction by these βAR subtypes, particularly β 2 AR, in the heart. It will attempt to unravel the intricacies of how multiple signals are compartmentalized and integrated in space and time to achieve diversity and specificity for GPCR signaling. Furthermore, a conceptual framework for understanding the physiological and pathophysiological relevance of the coupling of GPCRs to multiple G proteins and of the coexistence of receptor subtypes will be provided.
Dichotomous Coupling of Native β 2 AR to G s and G i in the Heart
Cardiac tissue expresses at least two subtypes of βAR: β 1 AR and β 2 AR. In the heart, nonselective βAR stimulation activates the G s -AC-cAMP cascade, leading to PKA-dependent phosphorylation of a set of regulatory proteins involved in cardiac excitation-contraction coupling and energy metabolism, including L-type Ca 2+ channels, the sarcoplasmic reticulum (SR) membrane protein phospholamban (PLB), myofilament proteins, and glycogen phosphorylase kinase. A hallmark of β 1 AR or mixed β-Adrenergic Signaling in the Heart: Dual Coupling of the β 2 -Adrenergic Receptor to G s and G i Proteins Rui-Ping Xiao (Published 16 October 2001) βAR stimulation is to increase cardiac contractility (positive inotropic effect), accelerate cardiac relaxation (positive lusitropic effect), and increase heart rate (positive chronotropic effect). However, in adult rat ventricular myocytes, although stimulation of both βAR subtypes increases the amplitudes of L-type Ca 2+ currents (I Ca ), intracellular Ca 2+ transient, and contraction strength, β 2 AR stimulation fails to accelerate the decay of the intracellular Ca 2+ transient and the contractile relaxation (11, 12) . The absence of β 2 AR-mediated relaxation occurs in many other mammalian species, including cats and sheep (13, 14) , but not in humans and dogs (15) (16) (17) (18) . These observations provide the first clue that there can be substantial differences in intracellular signal transduction pathways initiated by β 2 AR, compared to those activated by β 1 AR. In the search for the answer to the "anomalous" behavior of cardiac β 2 AR stimulation, studies over the past decade have provided evidence for the coupling of native β 2 AR to at least two pathways under physiological conditions. Studies using physiological conditions at the single-cell level demonstrated that disrupting G i signaling by pertussis toxin (PTX)-mediated G i ribosylation markedly enhances β 2 AR-induced contractile response in rat and mouse ventricular myocytes (19, 20) . These results suggest that PTX-sensitive G i proteins may partially negate the G s -mediated contractile response in cardiac myocytes. Moreover, photoaffinity labeling of G proteins with [ 32 P]azidoanilide-GTP in conjunction with immunoprecipitation of endogenous G proteins with antibodies specific for Gα s and Gα i provided direct biochemical evidence that native β 2 AR interacts with both G s and G i (specifically, G i2 and G i3 ) signaling pathways in freshly isolated adult mouse cardiac myocytes (20) . The maximal effect of β 2 AR stimulation on the G i proteins in the mouse cardiomyocytes is comparable to that induced by carbachol, a muscarinic acetylcholine M 2 receptor agonist (20) . PTX treatment or application of a β 2 AR antagonist (ICI 118,551) prevents the β 2 AR-mediated activation of G i . Under the same experimental conditions, β 1 AR stimulation does not increase G i activity; thus, the coupling to G i is specific for β 2 AR (20) . Similarly, in human myocardium, cardiac G i is activated by stimulation of β 2 AR; this property is not shared by β 1 AR (21). Thus, whereas β 1 AR activates only the G s pathway, β 2 AR can activate both G s and G i signaling pathways.
Several other GPCRs, including histamine, serotonin, and glucagon receptors, stimulate both G s and G i proteins in human heart (21) . Thus, multiple G protein coupling appears to be rather common, albeit not universal, among GPCRs. These findings raise important questions regarding the consequences of coupling one receptor to multiple G proteins in physiological and pathophysiological contexts. β 2 AR-to-G i Signals Compartmentalize G s -Mediated cAMP Signaling A species-dependent diversity has been documented with respect to β 2 AR-stimulated cAMP accumulation and PKA activation. In the human heart, β 2 AR stimulation efficiently increases cellular cAMP and PKA-dependent phosphorylation of intracellular regulatory proteins [PLB, troponin-I (TnI), and C protein], similar to β 1 AR stimulation (15, 16, 22) . In freshly isolated canine ventricular myocytes and cultured 18-day embryonic mouse cardiomyocytes, however, β 2 AR elevates neither total cellular cAMP nor PKA activity, whereas β 1 AR induces a robust increase in cAMP accumulation under the same experimental conditions (17, 18, 23) . Between these extremes, in freshly isolated rat ventricular myocytes, the dose-response of cAMP to β 2 AR overlaps that to β 1 AR stimulation (12, 24, 25) . Nevertheless, both biochemical evidence and biophysical evidence indicate that β 1 AR-generated cAMP signaling can broadcast throughout the cell, whereas β 2 AR-initiated cAMP signaling is confined to subsarcolemmal microdomains (26) . Specifically, in adult rat and canine hearts, β 1 AR stimulation increases phosphorylation of PLB, which accelerates Ca 2+ sequestration into SR, resulting in accelerated cardiac relaxation (11, 17-19, 24, 27, 28) . β 1 AR stimulation also promotes phosphorylation of TnI and C protein (18) , which reduces myofilament sensitivity to Ca 2+ . In contrast, β 2 AR stimulation modulates specifically sarcolemmal L-type Ca 2+ channels without affecting the aforementioned intracellular regulatory proteins in these species (11, 17-19, 24, 27, 28) . Furthermore, experiments with patch-clamp single-channel recordings showed that in rat cardiomyocytes, β 2 AR stimulation modulated single L-type Ca 2+ channel activity only in a local mode (agonist included within the patch pipette with tip diameter ~1.0 µm) and not in a remote mode (agonist perfused outside the patch), whereas β 1 AR stimulation acted in either mode (29) . These results are in general agreement with the observation that in frog cardiomyocytes, in which the β 2 AR subtype predominates (30) , local βAR stimulation by isoproterenol applied to one end of the cell has little stimulatory effect on L-type Ca 2+ channels residing on the other end (31) .
These studies initially evoked doubts as to whether the β 2 AR cardiac response is mediated by a cAMP-dependent signaling pathway. One theory proposed is that the cardiac effects of βAR (subtype not specified) might be, in part, mediated by a direct interaction between Gα s and L-type Ca 2+ channels (32, 33) . However, in other studies, except one in rat ventricular myocytes (34) , specific PKA inhibitors, including a peptide inhibitor (PKI), an inactive cAMP analog (RP-cAMP), and a synthetic compound (H-89), not only blocked the effects of β 1 AR stimulation, but also completely inhibited the effects of β 2 AR stimulation (18, 20, 27, 29) . [Although H-89 has been widely used as a PKA inhibitor, recent studies indicate that H-89 is also a potent blocker of both βAR subtypes (35)]. The results obtained through PKA inhibition corroborate the notion that the effect of nonselective βAR stimulation by isoproterenol on cardiac I Ca is mediated exclusively by a cAMP-dependent mechanism. Specifically, the I Ca response to isoproterenol is ablated by PKI (36) . Hence, the modulation of I Ca by β 2 AR should require cAMP-dependent PKA activation, but this β 2 AR-stimulated cAMP-to-PKA signaling appears to be tightly localized to the surface membrane in the vicinity of L-type Ca 2+ channels and cannot be transmitted to nonsarcolemmal proteins ( Fig. 1) .
Several lines of evidence indicate that activation of the β 2 AR-to-G i signaling pathway is essential for the spatial localization and effector selectivity of the G s -stimulated cAMP-to-PKA signaling. First, disrupting G i function with PTX permits β 2 AR to stimulate remote L-type Ca 2+ channels (29) . Second, PTX treatment leads to a robust β 2 AR-mediated phospholamban phosphorylation and a positive relaxant effect not normally present in β 2 AR cardiac signaling (19, 28) . Thus, coupling of the cardiac β 2 AR to multiple G proteins can paradoxically enhance, rather than compromise, the spatial and temporal specificity of the receptor signaling.
A challenging question is how β 2 AR-to-G i signaling results in the compartmentalization of β 2 AR-to-G s -to-cAMP signaling.
Possible mechanisms for limiting the cAMP signaling pathway include physical restriction of cAMP diffusion, a local imbalance between AC and phosphodiesterase activities, restriction of the diffusion of PKA, or regulation of the pathway downstream of PKA activity. The diffusible second messenger cAMP can traverse a micrometer-scale distance on a millisecond time scale; hence, it seems unlikely that limiting cAMP diffusion is the mechanism. There is evidence that compartmentalization is a consequence of regulation of the pathway downstream of PKA. PTX treatment, which abrogates the functional compartmentalization of β 2 AR-to-cAMP signaling in freshly isolated rat ventricular myocytes, has no significant effect on the β 2 ARmediated global cAMP accumulation or PKA activation (27, 28) . Other G i -coupled receptors, such as the muscarinic receptor M 2 or adenosine receptor A 1 , counteract the effect of PKA, in part, through activation of protein phosphatases (37, 38) . Emerging evidence suggests that inhibition of protein phosphatases with calyculin A, an inhibitor of phosphatases 1 (PP1) and 2A (PP2A), mimics the effects of PTX treatment and enhances β 2 AR-mediated positive contractile response (28) . Because the effects of PTX treatment and calyculin A are not additive, the mechanism by which β 2 AR-coupled G i signaling compartmentalizes the concurrent G s signaling may be through activation of protein phosphatase(s) (28) . Activation of the β 2 ARcoupled G i proteins stimulates a phosphoinositide 3-kinase (PI3K)-Akt (also known as protein kinase B) cell survival signaling pathway in rat and mouse cardiac myocytes (39, 40) (see below). A question to be answered is whether PI3K signaling also contributes to the G i -dependent localization of β 2 AR-tocAMP signaling; if so, it will be necessary to determine the relation of the PI3K signaling to the G i -activated protein phosphatases.
Another candidate mechanism underlying compartmentalization of cAMP signaling is the structural restriction of PKA diffusion by specific A-kinase anchoring proteins (AKAPs) (41, 42) . For example, a peptide inhibitor of AKAP can inhibit the modulation of L-type Ca 2+ channels by PKA, which suggests that AKAPs are necessary for targeting PKA to this substrate (43) . Interestingly, AKAPs not only traffic the bound PKA and other enzymes (such as protein phosphatases) to specific compartments, but also functionally modulate the activity of the bound enzymes. This is clearly demonstrated by the inhibition of PKA and stimulation of PP1 by certain AKAPs (44) (45) (46) . Increasing evidence indicates that direct interaction of β 2 AR with some AKAPs (such as gravin and AKAP79/150) is essential for agonist-induced β 2 AR trafficking and desensitization (47) (48) (49) (50) (51) . A potentially interesting question to be examined is whether AKAPs participate in the G i -dependent compartmentalization of the β 2 AR to G s -mediated cAMP signaling.
AR-to-G i Coupling Delivers Cell Survival Signals
In addition to the modulation of cardiac excitation-contraction coupling by acute βAR stimulation, as discussed above, both in vivo and in vitro studies have shown that prolonged βAR signaling stimulates cardiac myocyte apoptosis (52) (53) (54) . Apoptosis has been implicated in cardiac ischemic and reperfusion injury and is involved in the transition from cardiac hypertrophy to decompensated heart failure (55) (56) (57) (58) (59) . Pharmacological evidence suggests that β 1 AR and β 2 AR stimulation may exert different effects on cardiac cell survival (60, 61) . To avoid complicated interactions between βAR subtypes, we created a genetically "pure" β 1 AR or β 2 AR experimental system by individually expressing either βAR subtype in the null background of β 1 AR and β 2 AR double-knockout adult mouse cardiac myocytes in culture (40, 62) . These studies provided evidence that stimulation of β 1 AR leads to cardiac apoptosis, whereas stimulation of β 2 AR activates concurrent proapoptotic and antiapoptotic signals, with the net effect being cell survival (40) . The distinct effects of β 1 AR and β 2 AR on cardiac cell survival and cell death have been further confirmed using gene-targeted mice lacking either βAR subtype or in cultured wild-type adult mouse ventricular myocytes using βAR subtype-selective agonists and antagonists (63) .
These differences between the two βAR subtypes might be simply explained by their differential coupling to cAMP. However, this is unlikely because cardiac-specific overexpression of adenylyl cyclase types V or VI in transgenic mouse models markedly increases cAMP and cardiac contractility without apoptotic effects (64, 65) . In transgenic mouse hearts or cultured adult mouse cardiomyocytes, overexpression of human β 2 AR significantly elevates basal cAMP level but is not associated with myocyte apoptosis (66) (67) (68) . In addition, it has been suggested that myocyte apoptosis induced by β 1 AR stimulation is independent of cAMP signaling (69) .
Alternatively, the differential regulation of cardiac cell survival and cell death by these βAR subtypes can be explained by the additional coupling of β 2 AR to PTX-sensitive G i proteins. This conclusion is supported by several independent lines of evidence. First, β 2 AR stimulation leads to myocyte apoptosis only under conditions in which G i is inhibited with PTX (40). Second, β 2 AR, but not β 1 AR, activates a G i -Gβγ-PI3K-Akt signaling pathway. Inhibition of G i -to-Gβγ signaling with PTX or βARK-ct (a peptide inhibitor of Gβγ signaling), or inhibition of PI3K activity with LY294002, completely abolishes β 2 AR-stimulated Akt activation; more important, it converts β 2 AR signaling from survival to apoptotic (40) . Therefore, PI3K constitutes an intracellular messenger of the β 2 AR-to-G i pathway, which protects myocytes against G s -mediated apoptosis through activation of the survival factor Akt (Fig. 1) . Third, pretreatment of cultured neonatal rat cardiac myocytes with β 2 AR agonists (zinterol or isoproterolol plus a β 1 AR antagonist, CGP20712A) protects these myocytes from a range of apoptotic assaults, including hypoxia or reactive oxygen species (ROS), through the G idependent, PI3K-mediated mechanism (39) .
In addition to the PI3K survival pathway, it has been suggested that in cultured adult rat cardiac myocytes, both βAR subtypes activate p38 mitogen-activated protein kinase (MAPK) in a G i -dependent manner, and that the activated p38 MAPK results in an antiapoptotic effect (70) . However, this finding contradicts earlier observations from the same laboratory that β 1 AR and β 2 AR exhibit opposing effects on cardiac myocyte apoptosis because of the specific G i coupling to β 2 AR, but not β 1 AR (60). In fact, evidence obtained from the mouse β 1 AR-β 2 AR knockout system argues against the possibility that p38 MAPK is involved in β 2 AR-mediated cardiac myocyte survival. This is because both β 1 AR and β 2 AR increase p38 MAPK activation through a cAMP-to-PKA signaling pathway, but not by a G i -dependent mechanism (40, 71) , and because pharmacological inhibition of p38 by SB 203580 (10 µM) cannot block the β 2 AR survival effect. These studies indicate that p38 MAPK activation is not related to the β 2 AR-stimulated, G i -mediated antiapoptotic effect in adult mouse cardiac myocytes (40) . Further-more, in vivo activation of p38 MAPKs using transgenic overexpression of activated mutants of upstream kinases MKK3bE and MKK6bE neither induces nor suppresses cardiomyocyte apoptosis or hypertrophy in mice (72) . Thus, it appears unlikely that p38 MAPK plays an essential role in β 2 AR-induced antiapoptotic effect.
Other members of the MAPK family, particularly the extracellular signal-regulated protein kinases (ERK1 and ERK2), can also protect cells from apoptosis (73, 74) . Stimulation of β 1 AR or β 2 AR is able to activate ERK1 and ERK2 in multiple cell types, including cardiac myocytes (39, 75, 76) . Interestingly, the effect of β 2 AR, but not β 1 AR, on ERK is markedly attenuated by PTX treatment, which suggests that ERK is a downstream target of β 2 AR-coupled G i signaling (39) . However, inhibition of ERK activation with the inhibitor PD98059, which inhibits the upstream kinase MEK1, cannot prevent a β 2 AR-mediated antiapoptotic effect (39).
Molecular and Cellular Mechanisms Underlying β 2 AR-to-G i Coupling
The mechanisms underlying the differential coupling of βAR subtypes to G proteins are not well understood. Multiple hierarchical mechanisms may act in concert to render the subtypespecific βAR-to-G protein interaction. At the molecular level, β 1 AR and β 2 AR are genetically distinct entities. The human β 1 AR gene is located at chromosome 10 and encodes a protein of 477 amino acids (77) , whereas the β 2 AR gene is located on chromosome 5 and encodes a protein of 413 amino acids (78) . The sequences of β 1 AR and β 2 AR share 71% and 54% amino acid identity in the seven transmembrane spanning domains and in overall sequence, respectively (77-79). Studies on chimeric or mutated G protein-coupled receptors (including the major subtypes of α-and β-adrenergic receptors) have shown that the third intracellular loop of these receptors is an important structural determinant for G protein coupling (80) (81) (82) . The third intracellular loop of β 1 AR is considerably longer than its β 2 AR counterpart because of the presence of a proline-rich motif that has been implicated as a negative modulator of βAR-G s coupling. This may, at least in part, explain the difference in the efficacy of β 1 AR and β 2 AR coupling to G s and AC (83, 84) . Our preliminary results suggest that replacement of the third intracellular loop and the COOH-terminal tail of β 1 AR with those of β 2 AR allows the chimeric receptor to activate both G i and G s signaling pathways (85) . Thus, the distinct G protein coupling of β 1 AR and β 2 AR could eventually be ascribed to some critical differences in the sequences of the third intracellular loops and the COOH-terminal tails of the receptors. Furthermore, a potential contribution of receptor posttranslational modifications to receptor-G protein selectivity has been demonstrated in HEK 293 cells, in which PKA-mediated phosphorylation of β 2 AR switches the receptor coupling preference from G s to G i (75) .
The distinct G protein coupling of these βAR subtypes might, to some extent, be attributable to differential subcellular localization of the receptor subtypes and G proteins. In the absence of agonist stimulation, β 1 ARs are enriched in noncaveolar cell surface membranes, whereas β 2 ARs are located predominantly in the caveolar membrane fraction of cardiac myocytes (86) . The difference in the subcellular distribution of βAR subtypes suggests that β 2 AR might physically colocalize with G i proteins, so that G i proteins are preferentially accessible to β 2 ARs. This hypothesis is further supported by the fact that Gα i proteins are most abundant in caveolae, whereas Gα s and Gβγ subunits are distributed in both caveolar and noncaveolar cell surface membranes in cardiac myocytes (86) .
AR-to-G i Signaling in Developing Hearts
In contrast to the situation in adult cardiac myocytes, the β 2 ARmediated contractile response is insensitive to PTX treatment in neonatal rat cardiac myocytes (87) . In those cells, β 2 AR stimulation, like β 1 AR, induces phosphorylation of PLB and TnI, and accelerates contractile relaxation (12) . The dose-response curve of contraction in response to the β 2 AR agonist zinterol is shifted ~2 orders of magnitude leftward in neonatal myocytes, as compared to that of adult myocytes. Thus, β 2 AR may play a more important role in mediating the contractile response to catecholamines in the noninnervated neonatal heart than in the innervated adult heart. This developmental change in cardiac β 2 AR responsiveness appears not to be caused by a difference in the amount of receptor expression, because there is no postnatal change in β 2 AR density (12) . The contraction dose-response to zinterol in neonatal rat myocytes (12) is similar to that in PTX-treated adult rat myocytes (19) . Thus, β 2 AR coupling to G i proteins might be acquired or reinforced by the onset of innervation during development or by agonist stimulation.
The lack of PTX sensitivity of β 2 AR contractile response in neonatal rat cardiac myocytes appears to contradict the fact that simultaneous β 2 AR stimulation and β 1 AR blockade results in an antiapoptotic effect through a G i -dependent survival pathway (39) , similar to the case in adult myocytes (40) . These studies suggest that in neonatal cardiac myocytes, β 2 AR-to-G i coupling is rather effective in regulating certain vital cellular processes such as cell survival, whereas it is relatively weak in terms of inhibiting the G s -mediated positive inotropic effect and phosphorylation of intracellular target proteins that control contraction. Thus, it is possible that the aforementioned compartmentalization mechanisms may not yet be in place in the developing heart.
Interaction Between β 2 AR and Other G i -Coupled Receptors
In cardiac myocytes, β 2 AR differs from β 1 AR regarding their interaction with several cardiac G i -coupled receptors. In neonatal rat ventricular myocytes, the β 1 AR-mediated cAMP accumulation and its inotropic and lusitropic effects are all prevented by M 2 -muscarinic acetylcholine receptor stimulation with carbachol. In contrast, the β 2 AR-induced cAMP accumulation and the inotropic effect persist in the presence of carbachol, although β 2 AR-stimulated phosphorylation of PLB and TnI and the lusitropic response are abolished by carbachol treatment (87) . Interestingly, in the absence of agonist stimulation, M 2 -muscarinic receptors colocalize with β 1 ARs, but not β 2 ARs, in noncaveolar cell surface membranes (88) . This may explain, in part, the differential interactions of M 2 receptors with β 1 ARs versus β 2 ARs.
In adult rat myocardium, there is also a striking difference between these βAR subtypes with respect to their cross-talk with G i -and G o -coupled δ-opioid receptors. A δ-opioid receptor agonist, leucine enkephalin, markedly inhibits β 1 AR-mediated positive inotropy (89, 90) . In contrast, leucine enkephalin has no effect on β 2 AR-mediated increase in cardiac contractility (89) , indicating that δ-opioid receptor signaling selectively interacts with cardiac β 1 AR, but not β 2 AR, signaling. The exact mechanism underlying the differential interaction of the βAR subtypes and G i -coupled receptors, both in neonatal and adult rat cardiomyocytes, merits further study. β 2 AR, but Not β 1 AR, Undergoes Spontaneous Activation According to the extended ternary complex model (91, 92) and the cubic ternary complex model (93) , GPCRs, including βARs, exist in an equilibrium of states, including two functionally and conformationally distinct states: an inactive conformation (R) and an active conformation capable of activating G proteins (R*) (66, 94, 95) . In the absence of a receptor ligand, the receptor can undergo a spontaneous transition to the activated state; the equilibrium between R and R* sets the level of basal receptor activation. Thus, the overexpression of a given receptor would be expected to proportionally increase the number of R* state receptors. Indeed, in a transgenic mouse model (TG4), cardiac-specific overexpression of β 2 AR by a factor of ~200 leads to an agonist-independent enhancement in both the baseline AC activity and myocardial contractility (20, 66, 95) . These results from the transgenic animals are corroborated by acute gene manipulation in cultured wild-type or β 1 AR-β 2 AR double-knockout adult mouse ventricular myocytes, in which adenovirus-directed overexpression of the human β 2 AR also results in agonist-independent increases in cellular cAMP production and in contractility (67, 68) . These studies suggest that cardiac contractility can be enhanced through genetically manipulating the β 2 AR system, which might hold therapeutic promise for improving the function of the failing heart. Studies on constitutively active GPCRs have suggested the concept of inverse agonists, that is, drugs that preferentially bind to R and inhibit basal receptor activity (66, 94, 95) . In this regard, ICI 118,551 has been identified as an inverse agonist of the β 2 AR. Although the two-state ternary complex model for the βAR is sufficient to explain many aspects of β 2 AR activation, there are several important differences between spontaneously activated β 2 ARs and agonist-stimulated β 2 ARs in terms of their effector selectivity. In TG4 ventricular myocytes, β 2 AR agonists produce a marked increase in I Ca , whereas ligand-independent constitutive β 2 AR activation increases cardiac contractility without affecting I Ca (96) . Hence, spontaneously activated β 2 AR and agonist-activated β 2 AR may represent functionally distinct conformational states of the receptor. This is in agreement with recent reports that β 2 ARs exhibit multiple active states (97, 98) .
The property of spontaneous activation is not shared by the β 1 AR, the predominant (75 to 85%) cardiac βAR subtype. In the mouse β 1 AR-β 2 AR null background, overexpression of β 1 AR to similar levels, or even greater levels, relative to overexpression of β 2 AR has virtually no effect on cAMP accumula-tion, contraction amplitude, or contractile kinetics (67) . These observations are consistent with the results from transgenic mice overexpressing β 1 AR (by a factor of 5 to 15 relative to the wild type) (99) . Apparently, β 1 AR, unlike β 2 AR, does not readily undergo spontaneous activation. Similarly, dopamine receptor subtypes 1A and 1B exhibit strikingly different constitutive activities (100). Thus, not all GPCRs appear to undergo spontaneous activation.
Pathophysiological Relevance of β 1 AR versus β 2 AR Signaling β 1 AR and β 2 AR manifest strikingly different or opposing effects on gene expression, cell growth, and cell death. Specifically, stimulation of β 1 ARs can produce hypertrophy in cultured neonatal rat cardiac myocytes through activation of a PI3K-Aktglycogen synthase kinase-3β (GSK-3β)-GATA4 (a member of zinc finger transcription factor family) signaling pathway (101, 102) . However, this appears to be independent of PTX-sensitive G i signaling (103) or ERK activation (101) . In addition, β 1 AR activation can exhibit robust apoptotic effects in vivo and in cultured adult myocytes (40, 60, 61, 104) . In sharp contrast, β 2 AR stimulation does not cause cardiomyocyte hypertrophy or apoptosis. Instead, β 2 AR activation protects myocytes against apoptosis induced by a wide array of assaulting factors, including enhanced β 1 AR signaling, hypoxia, and ROS (39, 40, 60) . Furthermore, chronic stimulation of each βAR subtype in the heart elicits distinctly different phenotypes and results in differences in prognosis in terms of cardiac hypertrophy and heart failure in transgenic mouse models. Overexpression of cardiac β 1 AR by a factor of 5 to 40 leads to cardiac hypertrophy, myocyte apoptosis, and fibrosis within a few weeks after birth, and heart failure within several months (99, 104) . Overexpression of cardiac β 2 AR by a factor of 100 to 200 does not produce hypertrophy or heart failure, at least up to the age of 1 year (66, 105, 106) . However, higher levels of expression of β 2 AR (such as 350 to 1000 times the normal levels) result in pathological phenotypes (105, 106) , perhaps caused by a mechanical and metabolic overload due to spontaneous β 2 AR activation. The opposing effects of βAR subtypes on cardiac myocyte growth and cell death may explain, at least in part, the inverse relationship between the plasma concentration of norepinephrine (with higher affinity for β 1 AR than for β 2 AR) and survival in patients with chronic heart failure (107) and the salutary effects of βAR blockade on morbidity and mortality in heart failure patients (108) . These insights into the cellular responses to βAR subtype stimulation also imply that the selective down-regulation of β 1 ARs in the failing heart (109-112) may represent a protective mechanism to slow the progression of cardiomyopathy and myocyte apoptosis. This idea is further supported by the fact that the second and third generations of relatively β 1 AR-selective blockers used clinically (such as metoprolol, bisoprolol, and carvedilol) effectively reduce mortality and morbidity of heart failure patients (113) , whereas for the first generation of nonselective βAR antagonists (such as propranolol), the drug intolerability rate is prohibitively high because of myocardial depression and worsening of cardiac contractile dysfunction (114) .
Although activation of β 2 AR-coupled G i protects cardiac myocytes against apoptosis, an imbalance of β 2 AR-initiated G s and G i signaling pathways may have pathological consequences. Chronic heart failure in human and animal models is characterized by a diminished contractile response to βAR stimulation (109-112, 115, 116) and is accompanied by an increase in the amount or activity of G i proteins (112, (115) (116) (117) (118) and a selective down-regulation of β 1 AR, leading to a higher β 2 /β 1 ratio (109) (110) (111) (112) . In light of the G s and G i dichotomy, the up-regulation of G i may participate in the reduced βAR inotropic effect in the decompensated failing heart. This idea is supported by the fact that PTX treatment restores the diminished βAR inotropic response in a rat myocardial infarction heart failure model (119) and in myocytes from failing human hearts (120) . On the basis of these findings, it is speculated that the selective down-regulation of β 1 AR and the up-regulation of β 2 AR to G i signaling in the functionally compensated hypertrophic heart or in the early stages of heart failure may represent a cardiac protective mechanism. This change in the balance of β 1 AR and β 2 AR signaling may protect against myocyte apoptosis and consequently slow the progression of cardiomyopathy and contractile dysfunction. However, exaggerated β 2 AR-to-G i signaling may blunt G s -mediated contractile support, contributing to the phenotype of decompensated heart failure.
Therapeutic Implications of Cardiac β 2 AR Signaling
Whether enhancing βAR signaling is beneficial or deleterious for the failing heart has been a matter of much controversy. The prevalent view is that chronically increasing nonselective βAR stimulation is toxic to the heart. However, the discovery of (i) the new paradigm of β 2 AR signaling (dual G protein coupling), (ii) the opposing effects of stimulation of these βAR subtypes on cardiomyocyte apoptosis, and (iii) the distinct phenotypes of cardiac-specific overexpression of β 1 AR versus β 2 AR underscore the necessity and importance of distinguishing β 2 AR signaling from that of β 1 AR in terms of their cardiac functional roles and therapeutic implications.
Selective enhancement of β 2 AR signaling may provide a therapeutic strategy for the prevention and treatment of chronic heart failure because of its evident antiapoptotic and positive inotropic effects. Indeed, crossing transgenic mice overexpressing moderate amounts of cardiac β 2 AR with transgenic mice overexpressing Gα q not only improves cardiac performance, but also reverses hypertrophy in the Gα q overexpression heart failure model (105). Because extremely high levels of β 2 AR overexpression fail to rescue the genetic mouse heart failure model and can be detrimental (105, 106) , caution must be exercised when designing therapies to enhance β 2 AR signaling so that the beneficial levels of activity are not exceeded. The beneficial effect of β 2 AR stimulation in the context of heart failure is clearly supported by the analysis of β 2 AR polymorphisms in chronic heart failure patients. The prognosis of heart failure patients with Ile 164 polymorphism (a Thr-toIle switch at amino acid 164 with reduced β 2 AR signaling efficacy) is much worse than the prognosis of patients without the β 2 AR variant (121) . Thus, moderate selective activation of the β 2 AR subtype may have beneficial effects in the failing heart. Given that epinephrine is a potent β 2 AR agonist, it would be interesting and informative to determine whether the beneficial effects of exercise might be, in part, attributable to increased cardiac β 2 AR stimulation by epinephrine.
Other βAR Subtypes in the Heart
The third class of βARs, β 3 AR, was previously named an "atypical βAR" and was considered genetically and pharmacologically different from either β 1 AR or β 2 AR (122, 123) . Recent studies provide strong evidence that β 3 ARs, important regulators of the physiologic properties of adipose tissue and the gastrointestinal tract (and thus the target for antiobesity and antidiabetic drugs), are also present in human cardiomyocytes. In contrast to β 1 AR and β 2 AR, they have been implicated as inhibitors of contractile function (124) , apparently through a PTX-sensitive G protein-dependent activation of a nitric oxide synthase pathway (125) . β 3 AR also plays an important role in regulating smooth muscle relaxation, which could reflexively influence cardiac contractility. It is noteworthy that β 3 AR function is up-regulated in the failing heart (126) , suggesting that enhanced β 3 AR signaling may contribute to the phenotype of chronic heart failure. Stimulation of β 3 AR activates both G s and G i signaling pathways in cultured neonatal cardiomyocytes from β 1 AR-β 2 AR double-knockout mice. In the absence of PTX, β 3 AR stimulation has a small and relatively brief inhibitory effect on the spontaneous cell contraction rate, whereas inhibition of G i with PTX unmasks a positive chronotropic effect (127) . In addition, a fourth βAR subtype has been reported to mediate positive chronotropic and inotropic effects in the human heart (128). This "receptor" is now described as a low-affinity state of the β 1 AR (129, 130) , although its genetic identity and pharmacological properties await confirmation.
Beyond G Protein Doctrine: G Protein-Independent βAR Signaling
Possible G protein-independent mechanisms underlying βAR-mediated cellular responses have also been demonstrated. For instance, physical binding of Na + /H + exchange regulatory factor (NHERF), an inhibitor of Na + /H + exchanger type 3 (NHE3), to a PDZ domain at the β 2 AR COOH-terminus relieves the NHERF inhibitory effect on NHE3 (131) . The relevance of this phenomenon to β 2 AR signaling in cardiomyocytes, however, has not yet been explored. Another observation in HEK 293 cells demonstrates that the COOH-terminal SH3 domain of the endophilin SH3p4 specifically binds to the proline-rich motif of the β 1 AR third intracellular loop (132) . This protein-protein interaction is implicated in promoting agonist-induced internalization and in decreasing the G s coupling efficacy of β 1 ARs (132). Thus, βAR signaling is highly diversified not only through coupling to multiple G proteins, but also through G protein-independent protein-protein interactions between βARs and various effector proteins.
Concluding Remarks
The discovery of the dichotomous coupling of β 2 AR to G s and G i has challenged the linear one receptor-one G protein paradigm of GPCR signaling in physiological systems. The additional G i coupling of β 2 AR creates a functional barrier that localizes the concurrent G s -mediated cAMP signaling, thus enhancing receptor signaling specificity and effector selectivity. The G i branch also delivers a G s -independent cardioprotective signal through the G i -Gβγ-PI3K-Akt pathway, which not only counteracts the G s -mediated apoptotic effect but also protects cells from a variety of apoptosis-triggering assaults. Further, the differential G protein coupling, to a large extent, accounts for the distinctly different physiological and pathological roles in the heart for β 2 AR versus those of β 1 AR. The delicate balance of G s and G i signaling in space and time might be crucial to normal cellular functions, whereas an imbalance may have important pathophysiological relevance and clinical implications. Thus, selectively targeting βAR signaling pathways might afford novel therapeutic strategies for improving the function of the failing heart. Furthermore, these advances in understanding the signaling pathways begin to unravel the logic of multiple G protein coupling of GPCRs and the coexistence of GPCR subtypes in a single cell.
